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Abstract
Background: In search of a suitable GSH-depleting agent, a novel copper complex viz., copper N-(2-
hydroxyacetophenone) glycinate (CuNG) has been synthesized, which was initially found to be a potential
resistance modifying agent and later found to be an immunomodulator in mice model in different doses.
The objective of the present work was to decipher the effect of CuNG on reactive oxygen species (ROS)
generation and antioxidant enzymes in normal and doxorubicin-resistant Ehrlich ascites carcinoma (EAC/
Dox)-bearing Swiss albino mice.
Methods: The effect of CuNG has been studied on ROS generation, multidrug resistance-associated
protein1 (MRP1) expression and on activities of superoxide dismutase (SOD), catalase (CAT) and
glutathione peroxidase (GPx).
Results: CuNG increased ROS generation and reduced MRP1 expression in EAC/Dox cells while only
temporarily depleted glutathione (GSH) within 2 h in heart, kidney, liver and lung of EAC/Dox bearing
mice, which were restored within 24 h. The level of liver Cu was observed to be inversely proportional
to the level of GSH. Moreover, CuNG modulated SOD, CAT and GPx in different organs and thereby
reduced oxidative stress. Thus nontoxic dose of CuNG may be utilized to reduce MRP1 expression and
thus sensitize EAC/Dox cells to standard chemotherapy. Moreover, CuNG modulated SOD, CAT and and
GPx activities to reduce oxidative stress in some vital organs of EAC/Dox bearing mice. CuNG treatment
also helped to recover liver and renal function in EAC/Dox bearing mice.
Conclusion: Based on our studies, we conclude that CuNG may be a promising candidate to sensitize
drug resistant cancers in the clinic.
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Background
Oxidative stress is linked to carcinogenesis as well as to
sensitivity or resistance of cancer cells to anticancer drugs
[1]. The involvement of reactive oxygen species (ROS) in
induction of apoptosis of various cancer cells, especially
drug resistant cancers is well known [2-4]. Often, the abil-
ity of a therapeutic agent to induce apoptosis of cancer
cells depends upon the ability of cancer cells to generate
ROS [5]. Moreover, low levels of ROS favor the expression
of ABC transporters like P-gp [6]. Drug resistant cancers
often show very low levels of ROS. This is usually due to
high intracellular reduced glutathione (GSH) levels [7,8]
and enhanced activities of antioxidant enzymes like glu-
tathione peroxidase (GPx), catalase (CAT) and superoxide
dismutase (SOD) [9]. On the other hand, GSH is also
required for phase II detoxification reactions, for example
phase II enzymes like glutathione S-transferase (GST) iso-
zymes require GSH for the conjugation of electrophilic
drugs and xenobiotics [10]. Therefore, high levels of GSH
and GST have been implicated in drug resistant tumors
[8,11,12].
It has been reported that the depletion of GSH by different
pharmacological agent modulates resistance to anticancer
drugs [8,13,14]. So far no systematic approach of lower-
ing GSH levels has been made, and the chemicals capable
of lowering GSH level and GST activity have no structure-
activity relationships [13,14]. Unfortunately, most com-
pounds lowering GSH are toxic at required doses [13,14].
Therefore, the search for compounds having high GSH-
depleting properties with low toxicity is of immense
importance in the field of reversal of multidrug resistance.
For this reason, we have developed a novel metal chelate
capable of depleting GSH at non-toxic doses. Previously,
we have reported the synthesis, toxicity and resistance
reversal activity of the complex, viz., copper N-(2-
hydroxyacetophenone) glycinate (CuNG) [15,16]. A sin-
gle administration of CuNG can overcome multidrug
resistance (MDR) in vivo in male Swiss albino mice bear-
ing doxorubicin (dox) resistant Ehrlich ascites carcinoma
(EAC/Dox) cells; CuNG in combination with dox
increases the survivality (~4.5 folds with respect to
untreated control) [16]. Moreover, CuNG treatment alone
at a lower dose (single administration) was found to com-
pletely heal EAC/Dox bearing animals from their tumor
through immunomodulation in vivo [17]. Since copper
has been reported by others to induce apoptosis by gener-
ation of ROS [18], and since CuNG is a copper(II) chelate,
it warranted a study on its effect on ROS generation,
which includes beside GSH, a number of antioxidant
enzymes, like GPx, SOD and CAT.
In the present investigation we report that in vivo treat-
ment of novel metal chelate (CuNG) in one hand induced
ROS and down-regulated surface multidrug resistance-
associated protein 1 (MRP1) expression in EAC/Dox cells,
and on the other hand increased activities of antioxidative
enzymes in vital organs like heart, lung and kidney which
might be involved in CuNG mediated decrease in ROS
levels in those organs. Moreover, CuNG got excreted




Reduced glutathione (GSH), 5,5'-dithio bis (2-nitroben-
zoic acid) (DTNB), Nitro Blue Tetrazolium (NBT) and cat-
alase were purchased from Sigma Chemical Company, St.
Louis, USA. Ortho dianisidine and xanthene oxidase were
purchased from Acros Organics, Geel, Belgium. Other
chemicals used were of highest purity available. Anti-
MRP1 polyclonal antibody was purchased from Santa
Cruz Biotech. Inc (SC).
Animals and Cell lines
Swiss albino mice, originally obtained from National
Institute of Nutrition, Hyderabad, India and reared in the
institute animal facilities, were used for all in vivo experi-
ments with prior approval of the institutional animal eth-
ics committee. Dox resistant Ehrlich ascites carcinoma
(EAC/Dox), which is also resistant against cisplatin, cyclo-
phosphamide and vinblastin [14] was developed and
maintained according to the methods described previ-
ously [14]. In brief, 1 × 106 EAC/Dox cells were inoculated
intraperitoneally (i.p.) into each mouse (weighing 18–22
gm, 6 weeks old) of experimental group(s) and main-
tained as an ascitic tumor. During experiments, ascitic
fluid containing EAC/Dox cells was drawn out aseptically
from peritoneal cavity of mice having 7–8 days of ascitic
tumor growth. Tumor cells were washed in phosphate
buffer saline (PBS, pH 7.4) and counted in a haemocy-
tometer by trypan blue exclusion method.
Treatment schedule of CuNG and Dox
CuNG was injected once i.p. at a dose of 10 mg/kg body
weight [dissolved in DMSO and finally suspended in nor-
mal saline to achieve final concentration of 0.1% (v/v)
DMSO in normal saline]. Untreated control group
received i.p. injection of 1 ml vehicle (i.e., 0.1% (v/v)
DMSO in normal saline) only. In EAC/Dox bearing mice,
CuNG was administered 7 days after inoculation with
EAC/Dox. Previous work from our laboratory had showed
that at a dose of 10 mg/kg body weight CuNG had no tox-
icity [15]. Animals were euthanasized 2 h or 24 h after
CuNG treatment unless mentioned otherwise.
Measurement of glutathione (GSH)
GSH was measured following the method of Sedlack and
Lindsay [19]. Briefly, tissue/1 × 106 cell homogenate in 0.1BMC Cancer 2006, 6:267 http://www.biomedcentral.com/1471-2407/6/267
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ml PBS was mixed with 2.4 ml EDTA (0.02 M), 2 ml
deionized water and 0.5 ml 50% TCA and centrifuged at
500 × g for 15 min at 4°C. 2 ml of supernatant was mixed
with 2 ml 0.4 M Tris buffer (pH 8.9). 50 μl 5,5'-dithio bis
(2-nitrobenzoic acid) [DTNB] (0.01 M) was added to the
mixture. Within 2–3 min of addition of DTNB, optical
density (OD) was measured at 412 nm. Protein was meas-
ured by using the Bradford Method [20].
Measurement of glutathione peroxidase (GPx) activity
GPx activity was measured from the tissue homogenate.
Tissue homogenate was prepared following the method of
Hafemann et al [21]. In brief, the animals were sacrificed,
the organs were dissected, dried and weighed. The
homogenate was prepared with 0.15 M KCl solution and
centrifuged at 10,000 rpm for 20 min at 4°C. The super-
natant was analysed according to the reported method
[21,22].
Measurement of catalase (CAT)
Catalase was measured by the reported method [21,23].
In brief, tissue homogenate was prepared using 0.1 M
phosphate buffer solution (PBS, pH7.4) and centrifuged
at 1,00,000 g for 1 h at 4°C. Tissue homogenate was trans-
ferred in 0.1 M PBS (pH 7.4) containing 0.45 M H2O2.
Aliquots of the mixture (0.5 ml) were removed at 20 S
intervals and added to 2.0 ml of solutions containing 0.2
mg/ml O-dianisidine, 0.015 mg/ml peroxidase and 0.81
mg/ml sodium azide. After 10-min incubation at room
temperature, 50% H2SO4 solution was added to stop the
reaction. The absorbance of the reaction mixture was
measured at 530 nm. One unit of enzyme activity (k) was
calculated as follows:
k' = (2.303/t) log [a/(a-x)] [a, starting conc. of H2O2; a-x,
H2O2 conc. after t time].
Measurement of Superoxide dismutase (SOD)
SOD was measured by the reported method [21,24]. In
brief, tissue homogenate was prepared using 0.1 M PBS
(pH 7.4) and centrifuged at 1,00,000 × g for 1 h at 4°C.
The supernatant was dialyzed overnight against 0.1 M PBS
(pH 7.4) and transferred to a reaction mixture containing
0.043 M Na2CO3 buffer (pH 10.2), 0.1 mM xanthine, 0.1
mM EDTA, 0.05 mg/ml bovine serum albumin, 0.025
mM nitro blue tetrazolium (NBT) and the sample. After
10 min preincubation at 25°C, the reaction was started
with 0.1 ml xanthine oxidase and incubation was per-
formed for 20 min at 25°C. After addition of 0.2 mM
CuCl2, the absorbance of the solution at 560 nm was
measured. The activity of SOD required to inhibit the level
of NBT reduction by 50% was defined as 1 unit of activity.
Measurement of serum copper level
For serum collection, mice were anesthetized and their
chests were cleaned with ethanol. Blood was obtained via
closed cardiac puncture by means of a 22-guage hypoder-
mic needle [25]. Blood from each group (CuNG treated
and untreated; normal and EAC/Dox bearing mice) was
taken in separate glass tubes, clotted, chilled to 4°C and
centrifuged for 20 min at 3,000 rpm. Serum was removed,
immediately filtered (0.22 μm) and stored at 4°C (if used
within 24 h) or frozen. To 100 μl serum taken in a test
tube, 3.9 ml of nitric acid (2.5%) was added and vortexed
for 5 min. The solutions were kept at 37°C incubator for
6 h with occasional shaking. The mixture was centrifuged
at 500 × g for 5 min. Cu was measured in the clear super-
natant in Flame Atomic Absorption Spectrophotometer
(AAS) [Varian Spectra 200 FS, hollow cathode lamp,
Flame type: Air acetylene; replicate 3; wavelength 324.8
nm].
Measurements of copper in liver tissue
Liver homogenate was prepared following the method of
Hafemann et al [21]. To 100 μl homogenate taken in a test
tube, 3.9 ml of nitric acid solution (2.5%) was added and
vortexed for 5 min. The solutions were kept at 37°C incu-
bator for 6 h with occasional shaking. The mixture was
centrifuged at 500 × g for 5 min. Cu was measured in the
clear supernatant by AAS.
Measurement of bile copper level
For bile collection, mice were anesthetized; chests were
cleaned with ethanol and opened. Whole gall bladder was
removed and total bile of gall bladder was dissolved in
100 μl double distilled water. To 100 μl bile solution 3.9
ml of nitric acid solution (2.5%) was added and vortexed
for 5 min. To avoid co-precipitation each sample was cen-
trifuged at 500 × g at 37°C. Cu was measured in the clear
supernatant by AAS.
Measurements of copper in urine
Mice were fed with excess amount of water with the help
of feeding needle and then urine was collected at different
time intervals like 4 h, 24 h and 48 h after CuNG injection
i.p. 100 μl urine was added to 3.9 ml of nitric acid solu-
tion (2.5%) and vortexed for 2 min. To avoid co precipi-
tation each sample was centrifuged at 500 × g at 37°C. Cu
was measured in the clear supernatant by AAS.
Measurements of copper in peritoneal fluid (PF)
Mice were anesthetized and peritoneal fluid was collected
at different time intervals like 4 h, 24 h and 48 h after
CuNG injection i.p. The maximum amount of peritoneal
fluid collected at 4 h was 500 μl; at 24 h and 48 h only 50
μl PF was collected. 50 μl PF was added to 1.95 ml of nitric
acid solution (2.5%) and vortexed for 2 min. To avoid coBMC Cancer 2006, 6:267 http://www.biomedcentral.com/1471-2407/6/267
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precipitation each sample was centrifuged at 500 × g at
37°C. Cu was measured in the clear supernatant by AAS.
Measurements of reactive oxygen species (ROS)
2 × 106 EAC cells from EAC/S bearing or EAC/Dox bearing
(untreated or CuNG treated) mice or 10 mg of tissue
(liver, lung, heart or kidney) in 1 ml of Hank's balanced
salt solution (HBSS) were taken and NBT assay for ROS
was performed according to Beauchamp and Fridovich
[26] with minor modifications. Tissues were homoge-
nized in tissue homogenizer. To each test sample, 0.5 ml
of NBT-HBSS (1 mg NBT/ml) was added and incubated at
37°C for either 4 h (in case of EAC cells) or 8 h (in case of
tissues). Then test samples were centrifuged and pellets
were washed thrice with methanol. Following this the
samples were dissolved in 1 ml 2 M KOH and 1 ml of
DMSO and then OD630 was measured. OD values were
compared with a standard curve constructed with NBT
and ROS generation was expressed as μM NBT equivalent/
2 × 106 cells or μM NBT equivalent/10 mg tissue.
Detection of surface MRP1 expression by flowcytometry
For the determination of surface MRP1 expression, EAC/
Dox cells were harvested from tumor-bearing mice and
incubated in presence of anti-MRP1 polyclonal antibody
following appropriate blocking. Cells were then washed
and incubated with anti-rabbit IgG-FITC conjugated sec-
ondary antibody. Following washing, cells were fixed with
paraformaldehyde and surface MRP1 expression was
determined on FACS, fluorescence detector equipped with
488 nm argon laser light source and 623 nm band pass fil-
ter (linear scale) using CellQuest software (Becton Dickin-
son). Appropriate isotype control was taken in all cases. A
total of 10000 events were acquired and analysis of flow
cytometric data was performed using ModFit software. A
histogram of FITC-fluorescence (x-axis) versus counts (y-
axis) has been displayed.
Detection of surface MRP1 expression by confocal 
microscopy
For the assessment of surface MRP1 expression, EAC/Dox
cells were incubated in presence of anti-MRP1 polyclonal
antibody following appropriate blocking. Cells were then
washed and incubated with anti-rabbit IgG-FITC conju-
gated secondary antibody. Following washing, cells were
fixed with paraformaldehyde and surface MRP1 expres-
sion was visualized using a confocal microscope (LSM
510; Carl Zeiss, Jena, Germany).
Statistical Analysis
Each experiment was performed 3 to 5 times and results
are expressed as mean ± SD or Student's t-test for signifi-
cance was performed and p < 0.01 was considered signifi-
cant. Flow cytometric and fluorescence microscopic data
show representative data of at least three independent
experiments.
Results
CuNG treatment in vivo could induce ROS generation by 
EAC/Dox cells and reduce their surface MRP1 expression
Increased ROS levels have been reported to reduce P-gp
expression [6]. The EAC/Dox cells were shown to over
express MRP1 [16] with respect to their sensitive counter-
part. Interestingly, overnight incubation of EAC/Dox cells
in presence of exogenous 50 μM H2O2 (which was non-
toxic concentration as manifested by >98% viability)
could also reduce surface MRP1 expression of these cells
(Fig. 1A). Therefore, ROS also plays a crucial role for the
maintenance of MDR phenotype in our cell model.
Since we have shown earlier that CuNG is a good resist-
ance modifier [16] and as copper has been reported to
induce apoptosis by generation of ROS [18], we tested
whether CuNG treatment in vivo could also increase ROS
generation in EAC/Dox cells. Interestingly, CuNG treat-
ment in vivo was found to induce ROS generation in EAC/
Dox cells by both NBT reduction (Fig. 1B) [>90% of the
NBT reduction was inhibitable by SOD (data not shown)]
as well as with H2O2 trapping dye, Dichlorofluorescein-
diacetetate (DCF-DA) and Cytochrome c reduction (data
not shown). This prompted us to investigate whether
CuNG treatment could inhibit MRP1 expression. It was
observed that in vivo CuNG treatment also decreased sur-
face expression of MRP1 in EAC/Dox cells within 3 days
(Fig. 1C). Interestingly, the surface MRP1 expression of
EAC/Dox cells isolated from CuNG treated mice was even
lower than that of EAC/S cells. This might be due to a con-
tributory effect of NO that was also produced upto 72 h
following CuNG treatment (data not shown). We have
also found that H2O2 along with sodium nitroprusside
caused a more profound down-regulation of MRP1
expression in EAC/Dox cells (data not shown).
CuNG treatment in vivo reduces ROS generation in heart 
and lung in EAC/Dox bearing mice
Since increased ROS generation in different vital organs
like heart, lung, liver and kidney may be toxic for these
organs, we determined whether CuNG treatment also
modulated ROS generation in these vital organs.
As shown in Fig. 2A, CuNG treatment in vivo reduced
ROS generation in heart and lung significantly (P < 0.01
and P < 0.001 respectively) in EAC/Dox bearing mice.
Interestingly enough, CuNG treatment increased ROS
generation in liver of these animals.
Since CuNG treatment in vivo modulated the ROS gener-
ation in vital organs, we studied the status of antioxidant
enzymes related to phase II detoxification in these organs.BMC Cancer 2006, 6:267 http://www.biomedcentral.com/1471-2407/6/267
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(A) Effect of exogenous H2O2 on MRP1 expression Figure 1
(A) Effect of exogenous H2O2 on MRP1 expression. EAC/Dox cells were incubated overnight in presence of 50 μM H2O2. Sur-
face MRP1 expression was studied by flow cytometry and confocal microscopy. Representative data of 5 independent experi-
ments is presented. (B) ROS generation by EAC/Dox cells ex vivo 24 h following in vivo CuNG treatment. CuNG treatment 
given after 7 days following inoculation with EAC/Dox cells. Results are compared with ex vivo ROS generation by EAC cells 
derived from EAC/S and EAC/Dox bearing mice. EAC/Dox cells following in vivo CuNG treatment and EAC/S cells generated 
significantly higher levels of ROS compared to EAC/Dox cells from untreated animals (*, P < 0.001 and **, P < 0.005). Results 
are presented as mean ± S.D. of 3 independent experiments. Each experiment was done with 5 animals in each experimental 
group. (C) Confocal microscopy of the effect of CuNG on MRP1 expression in EAC/Dox cells. EAC/Dox cells expressed 
higher levels of MRP1 than EAC/S cells and CuNG treatment reduced MRP1 expression. Results presented are representative 
of 3 independent experiments.BMC Cancer 2006, 6:267 http://www.biomedcentral.com/1471-2407/6/267
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(A) Effect of in vivo CuNG treatment on ROS generation in heart, kidney, liver and lung of normal and EAC/Dox bearing mice Figure 2
(A) Effect of in vivo CuNG treatment on ROS generation in heart, kidney, liver and lung of normal and EAC/Dox bearing mice. 
Results are presented as mean ± S.D. of 4 independent experiments, each involving 3 animals in each experimental group. 
Compared to untreated EAC/Dox bearing animals, In vivo CuNG treatment significantly increased ROS generation in kidney 
and liver, while decreased ROS generation in heart and lungs (*, P < 0.005 and **, P < 0.01). (B) Effect of in vivo CuNG treat-
ment on SOD, catalase and GPx activity in heart, kidney, liver and lung of normal and EAC/Dox bearing mice. Results are pre-
sented as mean ± S.D. of 5 independent experiments, each involving 4 animals in each experimental group. Compared to 
untreated EAC/Dox bearing animals, In vivo CuNG treatment significantly increased SOD activity in heart, kidney and lungs, 
while increased catalase activity in heart, kidney and liver (*, P < 0.005 and **, P < 0.01).BMC Cancer 2006, 6:267 http://www.biomedcentral.com/1471-2407/6/267
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Activities of SOD and CAT in heart, kidney, liver and lung 
in EAC/Dox bearing mice following CuNG treatment in 
vivo
The activity of SOD decreased in heart (~35%), kidney
(~5%) liver (~50%) and lung (~20%) (Fig. 2B upper
panel) in EAC/Dox bearing mice compared to their nor-
mal counterparts. Treatment with CuNG increased the
activity of SOD in heart by ~3 folds, in kidney by ~2.5
folds, in liver by 80% and in lung by ~35% with respect to
untreated EAC/Dox bearing mice.
CAT activity decreased in all vital organs like heart, kid-
ney, liver and lung in EAC/Dox bearing mice in compari-
son to normal mice (Fig. 2B, middle panel). Treatment of
CuNG in EAC/Dox bearing mice tremendously increased
CAT activity in heart (~5.5 folds) and kidney (~5 folds)
but the same was increased only ~30% in liver. Interest-
ingly, the CAT activity of lung remained almost
unchanged following CuNG treatment.
GPx activity was observed to be low in heart, kidney, and
lung of EAC/Dox bearing mice compared to normal mice
(Fig. 2B, lower panel). In EAC/Dox bearing mice CuNG
increased GPx activity only slightly in heart, kidney and
liver but moderately in lung (~30%) at 24 h post-treat-
ment.
Interestingly, the SOD activity of EAC/Dox cells (which
was observed to be slightly higher in these drug resistant
cells compared to their sensitive counterpart) was
observed to decrease by ~15% within 24 h following in
vivo CuNG treatment (data not shown). Although the cat-
alase activity remained more or less unchanged, the GPx
activity also increased to some extent in tumor cells fol-
lowing CuNG treatment of EAC/Dox bearing mice (data
not shown).
CuNG treatment temporarily alters levels of GSH in heart, 
kidney, liver and lung of EAC/Dox bearing mice
As GSH is important for scavenging ROS and maintaining
a reducing environment with in the cell, and since CuNG
depletes GSH in EAC/Dox cells, we have studied whether
CuNG treatment also lowers the GSH levels in heart, lung,
liver and kidney. GSH levels were low in these organs of
EAC/Dox bearing mice compared to that in their normal
counterparts. Although CuNG treatment depleted GSH in
all the organs tested by 2 h, the levels were restored by 24
h post treatment (Fig. 3), indicating that CuNG only tem-
porarily depleted GSH levels in these organs.
Status of liver and renal function following CuNG 
treatment
Since CuNG treatment increased ROS generation in liver
of EAC/Dox bearing mice, we tested different parameters
of liver and renal function to decipher whether there was
any apparent hepatic or renal toxicity following treatment
with CuNG.
As shown in Table 1, the levels of serum urea, serum gluta-
mate pyruvate transaminase (SGPT/ALT) and serum
glutamate oxaloacetate transaminase (SGOT/AST) levels
drastically decreased in EAC/Dox bearing mice in compar-
ison to their normal counterparts. CuNG treatment com-
pletely restored the SGOT level and partially restored the
SGPT and urea levels in serum within 24 h (Table 1). Alka-
line phosphatase (ALKP) levels in serum were comparable
in normal and EAC/Dox bearing mice. CuNG treatment
did not significantly alter serum ALKP level in EAC/Dox
bearing mice.
Excretion of copper following CuNG treatment
Accumulation of excess copper is known to be toxic.
Therefore, we were interested to know whether copper
was excreted or not following CuNG treatment.
After CuNG injection, released copper was measured in
bile, urine and in peritoneal fluid by AAS. Each mouse was
injected 180 μl solution of CuNG (1 mg/ml) i.p. that is
equivalent to 36.82 μg of Cu. Very high amount of copper
was released through urine (26.39 ± 1.6 μg) within 24 h.
The amount of copper excreted in bile was lower than that
of the urine (Fig. 4). We were able to collect 400 μl of peri-
toneal fluids within 2 to 4 h of CuNG injection, but after
24 h we collected only 25 μl peritoneal fluid. In CuNG
treated Swiss albino mice (6 week old, 18–22 gm weight)
the amount of urine collected was only 400 ± 23 μl/day.
After 24 h of CuNG injection, the volume of collected
urine reached the normal level i.e., 800–1000 μl/day.
High amounts of copper were excreted through bile
within 24 h of CuNG injection but reached almost to the
normal level within 48 h (Fig. 4) is indicative that CuNG
is metabolized in the liver and excreted through bile [27].
Discussion
ROS have multiple functions [1] and are implicated in
tumor initiation and progression [28-30] as well as in
induction of apoptosis of various cancer cells, including
drug resistant cancers [2-4]. Often, the ability of a thera-
peutic agent to induce apoptosis of cancer cells depends
upon the ability of those cancer cells to generate ROS [5].
Drug resistant cancers often show very low levels of ROS.
This is usually due to high intracellular GSH level [7] and
enhanced activities of antioxidant enzymes [8]. In the
present investigation, we have also found that the level of
ROS generation is lowered in EAC/Dox cells, which con-
tain high levels of intracellular GSH [16], compared to
their drug sensitive counterparts. Moreover, low levels of
ROS favor the expression of ABC transporters like P-gp [6]
on cancer cell surface. We have also found that an oxida-
tive environment reduced MRP1 expression on EAC/DoxBMC Cancer 2006, 6:267 http://www.biomedcentral.com/1471-2407/6/267
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cells. Interestingly, CuNG treatment, which resulted in
elevated ROS generation by EAC/Dox cells, could also
reduce their surface MRP1 expression. Elevation of ROS
generation by EAC/Dox cells following CuNG treatment
was quite expected as CuNG can deplete GSH that can
actively scavenge ROS [15,16]. The effect of oxidative
stress on P-gp has been well reported previously [6] but
the phenomenon of ROS mediated (as well as NO medi-
ated) down regulation of MRP1 expression, which has
been reported here, is less known. This has important
Table 1: Effect of CuNG on hepatic and renal functions of EAC/Dox bearing mice
Urea (mg/dL) ALKP (U/L) SGOT (U/L) SGPT (U/L)
EAC/Dox-bearing 25 ± 1.5 185 ± 5.5 174 ± 7.5 65 ± 6.0
EAC/Dox-bearing +CuNG (ip) 32 ± 2.1 181 ± 4.5 471 ± 12.5 96 ± 7.5
Normal 52 ± 3.5 182 ± 4.0 422 ± 11.5 120 ± 9.5
Effect of in vivo CuNG treatment on GSH levels 2 h and 24 h post-treatment in heart, kidney, liver and lung of EAC/Dox bear- ing mice Figure 3
Effect of in vivo CuNG treatment on GSH levels 2 h and 24 h post-treatment in heart, kidney, liver and lung of EAC/Dox bear-
ing mice. Results are compared with corresponding controls. Results presented as mean ± S.D. of 3 independent experiments, 
each involving 5 animals in each experimental group. GSH levels decreased significantly in all organs 2 h following CuNG treat-
ment in vivo in EAC/Dox bearing animals compared to their untreated counterparts (*, P < 0.01).BMC Cancer 2006, 6:267 http://www.biomedcentral.com/1471-2407/6/267
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implication in therapy. It was found that by suppressing
surface MRP1 expression, CuNG converted EAC/Dox cells
susceptible to dox induced killing. These cells were now
observed to accumulate dox and undergo apoptosis (data
not shown).
Although ROS is important for cell signaling and different
physiological processes [31-33], too much ROS level and
oxidative stress is harmful [34,35]. Since CuNG could ele-
vate ROS in EAC/Dox cells, we undertook further studies
on levels of ROS generation, activation status of different
antioxidant enzymes and GSH levels in different vital
organs like heart, lung, liver and kidney following CuNG
treatment. We observed that ROS levels increased in heart
and lung but not in liver and kidney in EAC/Dox bearing
mice compared to their normal counterparts. Interest-
ingly, CuNG treatment reduced ROS in heart and lung but
not in liver and kidney in EAC/Dox bearing mice. It has
been reported earlier that SOD is decreased in lung and
liver of cancer patients [36]. We have also observed a
decrease in SOD activity in heart, liver and lung, but not
in kidney of EAC/Dox bearing mice compared to their
normal counterparts. This might reflect stress following
EAC/Dox inoculation and body's response to try and
increase ROS generation. CuNG treatment strongly
increased SOD activity in all organs tested in EAC/Dox
bearing mice. On the other hand, CAT activity was
strongly increased in heart and kidney while the increase
in CAT activity in liver was only marginal in response to
CuNG treatment. Moreover, CuNG treatment caused a
significant (P < 0.05) increase of GPx activity in lung. Thus
oxidative stress is well countered by increase in SOD and
CAT activities in heart and kidney and by SOD and GPx in
lung following CuNG treatment in EAC/Dox bearing
mice. Furthermore, these data indicate that the ROS gen-
erating effect of CuNG might be masked by increased
SOD and CAT activity in different organs. Interestingly,
CuNG treatment could elevate ROS generation to high
levels in tumor tissues that was not observed in normal
tissues of cancer bearing mice. However, since CuNG
could efficiently depleted liver-GSH, an increase of ROS in
liver was expected. Indeed this was found in the present
investigation. This in turn might actually cause an oxida-
tive environment in the organ along with increased CAT
and GPx activities with detrimental effects to tumor cells
[6,8,37]. Decreased levels of SGPT (ALT), SGOT (AST)
and urea in EAC/Dox bearing mice may be indicative for
ensuing hepatic failure. CuNG treatment brought back
serum SGPT and SGOT to near normal values and also
elevated serum urea level to some extent indicating that
no hepatic damage may have occurred due to CuNG
induced oxidative stress in liver. Moreover, CuNG did not
significantly alter ROS generation in heart and decreased
ROS generation in kidney, although it increased ROS gen-
eration in lung and liver of normal animals (data not
Copper levels in serum, liver and in peritoneal fluid, bile and  urine of normal and EAC/Dox bearing mice following CuNG  treatment Figure 4
Copper levels in serum, liver and in peritoneal fluid, bile and 
urine of normal and EAC/Dox bearing mice following CuNG 
treatment. Results presented as mean ± S.D. of 6 independ-
ent experiments, each involving 3 animals in each experimen-
tal group.BMC Cancer 2006, 6:267 http://www.biomedcentral.com/1471-2407/6/267
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shown). Of course, the effect of CuNG on different organs
of normal animals is not a good indicator of its utility as
copper homeostasis is disturbed in drug resistant cancer
bearing animals [38]. Interestingly, CuNG was found to
have no suppressive effect on lymphoproliferation (data
not shown) and was rather found to reduce tumor-
induced immunosuppression [17].
Copper accumulation may lead to toxicity [39]. Since
CuNG is a copper complex, it increases the level of Cu in
the system. It has been reported that serum copper level
was elevated in animals and humans with cancer [38,40].
When CuNG was injected in EAC/Dox bearing mice, the
concentration of copper in serum and liver was also
increased and found to be highest at 2 h. As copper is
metabolized in liver [27] we studied its level in liver and
found that copper level in liver increased till 2 h following
CuNG injection and then decreased. The increase of liver
Cu was found to be inversely proportional to liver-GSH
level; the level of GSH has been found to be depleted by
50% after the injection of CuNG. Depletion of GSH by Cu
has previously been reported e.g., by CuSO4 [41,42]. Cu is
stored mostly as metallothionein (MT)-copper complexes
in the organism while the amounts of unbound free Cu is
almost negligible; upon copper injection, GSH binds to
Cu before the metal complexes with MT [41]. In the
present report the initial depletion of GSH with increase
in Cu level in the liver induced by CuNG may be due to
the formation of GS-CuNG complexes [16]. We had
reported some data on GS-CuNG conjugate [16]. The level
of copper rises initially in EAC/Dox cells following CuNG
treatment, which again quickly decreased within 2–3 h
due to expulsion of GS-CuNG conjugate [16]. The
detailed works on the structural aspect of GS-CuNG con-
jugate are being pursued. Conjugation with GSH is a well-
known mechanism of exclusion of xenobiotics from cells.
After CuNG administration most of the copper (serum-Cu
and liver-Cu) was eliminated from the system by 24 h and
some amount of copper might be stored in the system
(liver) possibly through the formation of Cu (I)-metal-
lothionein complex [41]. Similarly, copper level is
increased in different tissues initially after CuNG treat-
ment, which is decreased within 24 h (data not shown).
We have utilized the depletion of GSH to sensitize drug
resistant cancer cells with elevated GSH level to anticancer
drugs [16,43]. Moreover, CuNG acts as immunomodula-
tor at a lower dose and releases cytokines and overcomes
drug resistance [17]. We have also observed that CuNG
down-regulates the phosphorylation status of signaling
molecules like Akt, which is related to drug resistance and
cell-survival in EAC/Dox cells, as evidenced from the
observation that wortmanin pretreatment in vitro could
reduce MRP1 expression and sensitize drug resistant cells
(EAC/Dox) towards doxorubicin (unpublished data).
Conclusion
Thus, we conclude that besides reversing resistance
toward dox by depletion of GSH [16], CuNG could also
induce ROS generation and down regulation of surface
MRP1 expression in EAC/Dox cells. The depletion of GSH
following formation and expulsion of GS-CuNG conju-
gate might be partially responsible for elevation of ROS in
EAC/Dox cells. Interestingly, neither CuSO4  nor the
organic backbone (NG) could reduce surface MRP1
expression of the EAC/Dox cells. Moreover, CuNG could
modulate SOD, CAT and GPx to reduce oxidative stress in
heart and lung. CuNG treatment of EAC/Dox bearing
mice also restored SGPT and SGOT levels to almost nor-
mal values and thereby rescued them from liver failure.
Thus CuNG is not only a resistance modifier but it also
possesses tissue protective activity.
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